空间基因组学和转录组学的全球市场：市场规模和占有率分析（依技术、产品、应用和最终用户）、收入估算和需求预测（截至 2030 年）

主要亮点

到 2023 年，空间基因组学和转录组学市场价值将达到 4.205 亿美元，此后将以 18.2% 的复合年增长率扩大到 2030 年的 13.485 亿美元。这项发展的主要原因是： - 临床诊断、载体筛检和药物发现对这些技术的需求不断增加，以及遗传疾病数量的迅速增加。

多年来，空间基因组学和转录组学的主要应用已从研究转向药物发现和开发。空间方法现在被用来增进对癌症、神经系统疾病和传染病的瞭解。这些技术也可能满足对反应预测生物标记的需求，这是癌症患者未满足的重要临床需求。透过提高我们对肿瘤微环境的瞭解，这些生物标记可以帮助免疫疗法的发展。

随着生命科学领域的研究活动变得更加活跃，正在开发和临床试验的药物管线也不断增加。由于需要有效治疗的慢性病和传染病数量不断增加，各国政府正在资助生命科学研究和开发计画。生命科学研究事业得到了巨大的投资，带来了前所未有的科学进步。

市场洞察

北美是最大的市场，到 2023 年所占占有率约为 45%，预计未来几年将出现更强劲的增长。这是由于生物技术和製药行业的高研发活动，以及非洲大陆慢性病风险的增加。此外，非洲大陆拥有声誉卓着的医疗机构，政府也致力于发展研发设施。

预计亚太地区未来几年将以最快的速度成长。这是由于该地区的全球和国内公司对生命科学研究的投资增加，以及传染病和慢性病发病率的飙升。

未来几年，药物发现类别预计将以复合年增长率约 20% 的速度快速发展。旨在发现新药的生物技术和药物研究广泛开展，学术机构和公司之间开发新药的合作关係也在增加。

诊断和疾病分析将在未来几年内实现最高的复合年增长率。这是因为已经开发了专门的软体和工具来进行诊断。

耗材品类预计到2023年将以60%的占有率引领业界，并在未来10年继续引领业界。许多相关应用越来越多地使用试剂盒、试剂和各种其他消耗品，进一步推动了这个类别的成长。

到 2023 年，学术/研究机构类别将成为最大的细分市场，占据 40% 的占有率，而这一趋势预计将在未来 10 年持续下去。这可能是因为空间基因组调查更频繁地在学术研究机构中进行，以综合分析各种疾病。

在本报告中，我们分析了全球空间基因组学和转录组学市场，包括市场的基本结构和最新情况、主要推动和抑制因素，以及全球、依地区和主要领域的市场规模趋势展望（基于金额，2017-2030），我们依技术、产品、应用和最终用户、当前市场竞争状况以及主要公司的概况调查详细趋势。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依应用划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依应用划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第十一章中东非洲市场

第12章美国市场

• 概述
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依应用划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其产品列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• NanoString Technologies Inc.
• 10x Genomics Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Cantata Bio LLC
• S2 Genomics Inc.
• Natera Inc.
• Seven Bridges Genomics Inc.

第31章附录

Key Highlights

The spatial genomics & transcriptomics market was valued at USD 420.5 million in 2023, and it will rise to USD 1,348.5 million, powering at an 18.2% compound annual growth rate, by 2030.

This development is mainly because of the rising demand for these technologies for clinical diagnostics, carrier screening, and drug discovery, and the surging occurrence of genetic disorders.

Over the years, the main applications of spatial genomics and transcriptomics have shifted from research to drug discovery & development.

Now, spatial methods are being employed to enhance the understanding of cancer, neurological illnesses, and infections.

The need for predictive biomarkers of response, which are a key unmet clinical requirement of cancer patients, is also likely to be addressed by these technologies.

By improving the knowledge of the tumor microenvironment, these biomarkers assist in developing immunotherapies.

With the rising research activities in life sciences, the total pipeline activity in terms of underdevelopment drugs as well as clinical trials has increased.

Governments are funding in life sciences research & development projects because of the increasing incidence of chronic and infectious illnesses, which require efficient treatments.

Life sciences research undertakings are getting exceptional investment and resulting in scientific improvements like never before, with which substantially more medications than before have made it to the industry in the last few years.

Market Insights

North America was the largest contributor to the industry in 2023, with around 45% share, and it is likely to further propel at a robust rate in the coming years.

This is because of the significant R&D activities in the biotechnology and pharmaceutical industries, along with the increasing risk of chronic illnesses in this continent.

This expansion is also because of the presence of reputable healthcare organizations and a robust government emphasis on the development of R&D facilities in this continent.

APAC will propel at the fastest rate in the years to come. This will be because of the rising investment from both global and domestic firms in this region in life science research, and the surging incidence of infectious and chronic diseases.

The drug discovery category will advance at a faster CAGR, of approximately 20%, in the coming years.

The broad biotech and pharma research on track for the finding of new drugs and the increasing number of partnerships between the academic institutes and industry players for drug development.

Diagnostics and illness profiling will propel at the highest compound annual growth rate in the coming years. This is because of the development of specialized software and tools for diagnostics.

The consumables category led the industry in 2023, with a 60% share, and it will remain leading throughout this decade.

The increasing utilization of kits, reagents, and various other consumables for many associated applications further boost this category expansion.

The academic and research institutes category was the largest contributor in 2023, with a 40% share, and it is likely to continue this trend throughout this decade.

This can be because spatial genomic studies are being conducted more often in academic research facilities for a comprehensive analysis of different illnesses.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by technique
  • 1.4.2. Market size breakdown, by product
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Technology (2017-2030)
• 6.3. Market Revenue, by Product (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Technology (2017-2030)
• 7.3. Market Revenue, by Product (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Technology (2017-2030)
• 8.3. Market Revenue, by Product (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Technology (2017-2030)
• 9.3. Market Revenue, by Product (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Technology (2017-2030)
• 10.3. Market Revenue, by Product (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Technology (2017-2030)
• 11.3. Market Revenue, by Product (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Technology (2017-2030)
• 12.3. Market Revenue, by Product (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Technology (2017-2030)
• 13.3. Market Revenue, by Product (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Technology (2017-2030)
• 14.3. Market Revenue, by Product (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Technology (2017-2030)
• 15.3. Market Revenue, by Product (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Technology (2017-2030)
• 16.3. Market Revenue, by Product (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Technology (2017-2030)
• 17.3. Market Revenue, by Product (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Technology (2017-2030)
• 18.3. Market Revenue, by Product (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Technology (2017-2030)
• 19.3. Market Revenue, by Product (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Technology (2017-2030)
• 20.3. Market Revenue, by Product (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Technology (2017-2030)
• 21.3. Market Revenue, by Product (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Technology (2017-2030)
• 22.3. Market Revenue, by Product (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Technology (2017-2030)
• 23.3. Market Revenue, by Product (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Technology (2017-2030)
• 24.3. Market Revenue, by Product (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Technology (2017-2030)
• 25.3. Market Revenue, by Product (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Technology (2017-2030)
• 26.3. Market Revenue, by Product (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Technology (2017-2030)
• 27.3. Market Revenue, by Product (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Technology (2017-2030)
• 28.3. Market Revenue, by Product (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. NanoString Technologies Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. 10x Genomics Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Illumina Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Bio-Rad Laboratories Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. PerkinElmer Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Thermo Fisher Scientific Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. F. Hoffmann-La Roche Ltd.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Cantata Bio LLC
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. S2 Genomics Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Natera Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Seven Bridges Genomics Inc.
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports